Advances in cystic fibrosis gene therapy
- PMID: 15510064
- DOI: 10.1097/01.mcp.0000142102.91202.04
Advances in cystic fibrosis gene therapy
Abstract
Purpose of review: The first cystic fibrosis gene therapy trials were carried out in 1993, and although proof-of-principle for gene transfer to the lungs was established, efficiency was generally low. The authors review the most recent advances in preclinical airway gene transfer and summarize the results from the latest clinical trials.
Recent findings: Recent clinical trials report encouraging results. Repeat administration of adeno-associated virus to the lung was safe. Nonviral nanoparticles used, for the first time, in the nose of cystic fibrosis patients were also safe and led to partial correction of the chloride transport defect in nasal epithelium. Important advances have been made in preclinical research, including the development of new viral and nonviral gene transfer agents and improved plasmid DNA. In addition, physical delivery methods, such a magnetofection and electroporation, are being assessed to improve nonviral gene transfer.
Summary: Considerable progress has been made in understanding and overcoming the problems associated with gene transfer to airway epithelial cells, the target cells for cystic fibrosis gene therapy. It has also been recognized that novel preclinical and clinical assays are crucial for the success of cystic fibrosis gene therapy, and considerable effort is currently being put into assay development and trial designs.
Similar articles
-
Update on gene therapy for cystic fibrosis.Curr Opin Mol Ther. 2003 Oct;5(5):489-94. Curr Opin Mol Ther. 2003. PMID: 14601517 Review.
-
Gene therapy for cystic fibrosis.Proc Am Thorac Soc. 2010 Nov;7(6):408-14. doi: 10.1513/pats.201004-029AW. Proc Am Thorac Soc. 2010. PMID: 21030522 Review.
-
Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial.Lancet. 1999 Mar 20;353(9157):947-54. doi: 10.1016/s0140-6736(98)06532-5. Lancet. 1999. PMID: 10459902 Clinical Trial.
-
Novel molecular approaches to cystic fibrosis gene therapy.Biochem J. 2005 Apr 1;387(Pt 1):1-15. doi: 10.1042/BJ20041923. Biochem J. 2005. PMID: 15656784 Free PMC article. Review.
-
A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis.N Engl J Med. 1995 Sep 28;333(13):823-31. doi: 10.1056/NEJM199509283331302. N Engl J Med. 1995. PMID: 7544439 Clinical Trial.
Cited by
-
Role of the Purinergic P2Y2 Receptor in Pulmonary Hypertension.Int J Environ Res Public Health. 2021 Oct 20;18(21):11009. doi: 10.3390/ijerph182111009. Int J Environ Res Public Health. 2021. PMID: 34769531 Free PMC article. Review.
-
Nanodelivery in airway diseases: challenges and therapeutic applications.Nanomedicine. 2010 Apr;6(2):237-44. doi: 10.1016/j.nano.2009.07.001. Epub 2009 Jul 16. Nanomedicine. 2010. PMID: 19616124 Free PMC article. Review.
-
Human pluripotent stem cells for modelling human liver diseases and cell therapy.Curr Gene Ther. 2013 Apr;13(2):120-32. doi: 10.2174/1566523211313020006. Curr Gene Ther. 2013. PMID: 23444872 Free PMC article. Review.
-
Preparation, characterization, cytotoxicity and transfection efficiency of poly(DL-lactide-co-glycolide) and poly(DL-lactic acid) cationic nanoparticles for controlled delivery of plasmid DNA.Int J Pharm. 2007 Oct 1;343(1-2):247-54. doi: 10.1016/j.ijpharm.2007.05.023. Epub 2007 May 18. Int J Pharm. 2007. PMID: 17611054 Free PMC article.
-
Use of suppression-subtractive hybridization to identify genes in the Burkholderia cepacia complex that are unique to Burkholderia cenocepacia.J Bacteriol. 2005 Aug;187(15):5278-91. doi: 10.1128/JB.187.15.5278-5291.2005. J Bacteriol. 2005. PMID: 16030222 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials